Rita Lombardi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3879378/publications.pdf

Version: 2024-02-01

11	329	1163117 8	1281871 11
papers	citations	h-index	g-index

11	11	11	717
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. Cancers, 2022, 14, 646.	3.7	5
2	Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. Cancers, 2022, 14, 695.	3.7	3
3	HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Molecular Oncology, 2021, 15, 1005-1023.	4.6	8
4	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. Journal of Experimental and Clinical Cancer Research, 2020, 39, 213.	8.6	26
5	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 732.	3.7	22
6	Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. Journal of Experimental and Clinical Cancer Research, 2019, 38, 317.	8.6	82
7	Novel pathways involved in cisplatin resistance identified by a proteomics approach in nonâ€smallâ€cell lung cancer cells. Journal of Cellular Physiology, 2019, 234, 9077-9092.	4.1	11
8	Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 184-200.	1.6	83
9	Proteomic characterization of peroxisome proliferatorâ€activated receptorâ€Î³ (PPARÎ³) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. Molecular Oncology, 2016, 10, 1344-1362.	4.6	16
10	Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. Oncotarget, 2015, 6, 5324-5341.	1.8	20
11	Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. Oncotarget, 2015, 6, 25074-25092.	1.8	53